Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | BPH Global Ltd (BP8.ASX) |
|---|---|
| Release Time | 30 Jan 2026, 6:04 p.m. |
| Price Sensitive | Yes |
BPH Global Delivers Strong Quarterly Results
- Completed $1.1 million capital raise to fund growth
- Recorded record monthly sales of $551,627 in Indonesia
- Expanding seaweed sourcing and processing capabilities
- Advancing R&D programs for seaweed-based products
BPH Global Limited (ASX: BP8), a plant-based biotechnology company, released its Appendix 4C and Quarterly Activities Report for the period ended 31 December 2025. The company continued strong engagement with investors, securing $1.1 million in funding through a placement. During the quarter, BPH Global focused on consolidating and scaling its Indonesia-based seaweed trading operations, strengthening customer relationships, expanding sourcing capacity, and enhancing operational efficiency. The company recorded its strongest monthly trading performance to date in Month 6, generating gross sales of approximately A$551,627 (IDR 5,930,000,000). This was followed by a seasonal impact in Month 7, but the company rebounded strongly in Month 8, recording its second-highest monthly result of A$386,404.45 (IDR 4,519,000,000). BPH Global also continued to progress its research and development initiatives, including the appointment of an experienced aquaculture executive to its R&D Advisory Board, advancing mineral extraction research, and expanding into seaweed-based natural formulations for male vitality and performance. The company also continued to explore seaweed-based bioremediation opportunities to address environmental challenges in Indonesia.
BPH Global reported record monthly sales of A$551,627 in Month 6 and A$386,404.45 in Month 8 of the December quarter, representing the company's two highest monthly trading performances since commencing operations in May 2025.
BPH Global enters 2026 focused on scaling volumes, further broadening sourcing networks, deepening customer relationships, and increasing export activity under its Indonesian Seaweed Export Licence. The company is also advancing its R&D initiatives, including the development of seaweed-based bio-stimulant and natural formulation products.